Statements (89)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Anthrax_Vaccine_Adsorbed_(AVA)
|
| gptkbp:accessories |
addressed during public health emergencies
|
| gptkbp:advocates_for |
required for administration
|
| gptkbp:approves |
gptkb:2001
gptkb:U._S._Food_and_Drug_Administration with sterile water |
| gptkbp:associated_with |
bioterrorism threats
reduction in anthrax cases |
| gptkbp:availability |
limited to certain countries
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
post-exposure prophylaxis pre-exposure prophylaxis Phase III trials conducted used in outbreak situations |
| gptkbp:contains |
inactivated Bacillus anthracis spores
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
severe allergic reaction to components |
| gptkbp:developed_by |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:dosage_form |
3 doses
every 6 to 12 months for high-risk individuals |
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:historical_significance |
first vaccine approved for anthrax prevention
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bio Thrax
|
| gptkbp:indication |
gptkb:military_officer
laboratory workers handling anthrax first responders in anthrax outbreaks |
| gptkbp:invention |
patented
|
| gptkbp:is_a_resource_for |
available from health organizations
|
| gptkbp:is_available_on |
pre-filled syringes
|
| gptkbp:is_effective_against |
high in clinical studies
|
| gptkbp:is_used_for |
prevention of anthrax
|
| gptkbp:is_vulnerable_to |
inactivated vaccine
continues to evolve. subunit vaccine initial series followed by boosters 0, 7, and 21 or 28 days coordinated with public health agencies developed in response to bioterrorism threats. focus on improving stability and efficacy high efficacy in preventing anthrax disease inspired by historical anthrax outbreaks |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Emergent_Bio_Solutions,_Inc.
gptkb:United_States |
| gptkbp:marketed_as |
gptkb:United_States
trade name Bio Thrax |
| gptkbp:name |
gptkb:Anthrax_Vaccine_Adsorbed
|
| gptkbp:packaging |
single-dose vials
|
| gptkbp:part_of |
anthrax vaccination program
|
| gptkbp:price |
varies by provider
|
| gptkbp:produced_by |
gptkb:U._S._government
|
| gptkbp:provides_information_on |
provided by CDC
provided by WHO established for administration and use |
| gptkbp:public_awareness |
high due to anthrax risk
increased after bioterrorism events conducted to educate about anthrax risks critical for bioterrorism preparedness |
| gptkbp:receives_funding_from |
supported by government grants
|
| gptkbp:research |
ongoing for new formulations
ongoing for combination vaccines |
| gptkbp:safety_features |
generally well-tolerated
ongoing post-marketing surveillance |
| gptkbp:shelf_life |
up to 24 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever injection site reactions pain at injection site muscle aches rarely causes severe allergic reactions |
| gptkbp:suitable_for |
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:military_officer gptkb:World_Health_Organization pregnant women without consultation individuals with certain immune disorders laboratory workers handling anthrax individuals with certain autoimmune disorders pregnant women unless absolutely necessary |
| gptkbp:supply_chain |
managed by government agencies for emergency use
|
| gptkbp:target_audience |
adults at high risk of anthrax exposure
|
| gptkbp:targets |
gptkb:mythological_figure
|
| gptkbp:treatment |
recommended after exposure to anthrax spores
|
| gptkbp:type_of_insurance |
may vary by plan
|
| gptkbp:used_in |
biodefense programs
|